Wikipedia -WSS

Wikipedia

author：fashion 2025-09-27 16:23:46 - browse：474

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Trump surgeon general acknowledges mistakes during Covid

hotspot

WSS

The dental labor crisis is a moment of opportunity

Amazon on where the company's health care bets are headed next

Medicare threatens to cut off funding for HCA's Mission hospital

Crinetics acromegaly drug succeeds in late

Medicare threatens to cut off funding for HCA's Mission hospital

Readout LOUD podcast: How biotech is using artificial intelligence

focus

Wikipedia

hotspot

Psychedelics group wrestles with new pharma identity

Gilead might be held responsible for not developing a drug

Sports medicine is finally prioritizing gender equality

To avoid data mishandling cases, universities eye AI and other tools

Guidelines to prevent youth baseball injuries need more muscle

Covid hospitalizations on the rise, Humana says

Apple is now the first public company to be valued at $3 trillion

Trump surgeon general acknowledges mistakes during Covid

Jerome Adams on the need for new antivirals for Covid

Biogen Alzheimer’s drug launch off to slow start

knowledge

The 10 drugs up first for Medicare price negotiation

Gilead might be held responsible for not developing a drug

To avoid data mishandling cases, universities eye AI and other tools

Doctors' information doesn't help them choose wisely when sick

Listen: Biogen's potential pivot, & Illumina's next chapter

Biogen Alzheimer’s drug launch off to slow start

leisure time

leisure time

hotspot

focus